| 1 |
33461430 | Effect of 6 weeks of very low-volume high-intensity interval training on oral glucose-stimulated incretin hormone response. | 2022 Mar |
3 |
| 2 |
34490741 | Glucose-dependent insulinotropic polypeptide induces lipolysis during stable basal insulin substitution and hyperglycaemia in men with type 1 diabetes: A randomized, double-blind, placebo-controlled, crossover clinical trial. | 2022 Jan |
3 |
| 3 |
34687727 | Daily transient coating of the intestine leads to weight loss and improved glucose tolerance. | 2022 Jan |
1 |
| 4 |
34889083 | A novel integrated QSP model of in vivo human glucose regulation to support the development of a glucagon/GLP-1 dual agonist. | 2022 Mar |
1 |
| 5 |
34913553 | Beta cell function, incretin hormones, and incretin effect in obese children and adolescents with prediabetes. | 2022 Mar |
2 |
| 6 |
34916733 | Potential therapeutic effect of glucagon-like peptide-1 receptor agonists on COVID-19-induced pulmonary arterial hypertension. | 2022 Jan |
1 |
| 7 |
34932984 | Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. | 2022 Jan 4 |
2 |
| 8 |
35082201 | Effects of a new 75 g glucose- and high fat-containing cookie meal test on postprandial glucose and triglyceride excursions in morbidly obese patients. | 2022 Jan 27 |
1 |
| 9 |
35123462 | The gut hormone glucose-dependent insulinotropic polypeptide is downregulated in response to myocardial injury. | 2022 Feb 5 |
2 |
| 10 |
35193160 | Gastric inhibitory polypeptide as the new candidate for the interaction of skeletal muscle blood flow and glucose disposal. | 2022 Apr |
1 |
| 11 |
35232225 | Worsening Postural Tachycardia Syndrome Is Associated With Increased Glucose-Dependent Insulinotropic Polypeptide Secretion. | 2022 May |
1 |
| 12 |
35299971 | Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes. | 2022 |
1 |
| 13 |
35452190 | Roles of glucose-dependent insulinotropic polypeptide in diet-induced obesity. | 2022 Apr 22 |
2 |
| 14 |
35458186 | Neither Incretin or Amino Acid Responses, nor Casein Content, Account for the Equal Insulin Response Following Iso-Lactose Loads of Natural Human and Cow Milk in Healthy Young Adults. | 2022 Apr 13 |
1 |
| 15 |
35587193 | Glucose-dependent insulinotropic polypeptide secretion after oral macronutrient ingestion: The human literature revisited and a systematic study in model experiments in mice. | 2022 May 19 |
1 |
| 16 |
32886401 | Dose-dependent efficacy of the glucose-dependent insulinotropic polypeptide (GIP) receptor antagonist GIP(3-30)NH2 on GIP actions in humans. | 2021 Jan |
5 |
| 17 |
33045957 | Recent Medicinal Chemistry Approach for the Development of Dipeptidyl Peptidase IV Inhibitors. | 2021 |
1 |
| 18 |
33236115 | Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. | 2021 Jan 23 |
1 |
| 19 |
33247879 | Incretins in fibrocalculous pancreatic diabetes: A unique subtype of pancreatogenic diabetes. | 2021 Jun |
1 |
| 20 |
33712466 | GIP mediates the incretin effect and glucose tolerance by dual actions on α cells and β cells. | 2021 Mar |
1 |
| 21 |
33782700 | The Role of Incretins on Insulin Function and Glucose Homeostasis. | 2021 Jul 1 |
2 |
| 22 |
33791428 | A Non-Perturbative Molecular Grafting Strategy for Stable and Potent Therapeutic Peptide Ligands. | 2021 Mar 24 |
1 |
| 23 |
33839290 | GLP-1 peptide analogs for targeting pancreatic beta cells. | 2021 Aug |
1 |
| 24 |
33886495 | Effects of endogenous GIP in patients with type 2 diabetes. | 2021 May 21 |
1 |
| 25 |
33955602 | Pancreatic polypeptide: A potential biomarker of glucose-dependent insulinotropic polypeptide receptor activation in vivo. | 2021 Aug |
2 |
| 26 |
34310013 | The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update. | 2021 Sep |
1 |
| 27 |
34334589 | Acromegaly Cases Exhibiting Increased Growth Hormone Levels during Oral Glucose Loading with Preadministration of Dipeptidyl Peptidase-4 Inhibitor. | 2021 |
3 |
| 28 |
34405256 | The effect of 6-day subcutaneous glucose-dependent insulinotropic polypeptide infusion on time in glycaemic range in patients with type 1 diabetes: a randomised, double-blind, placebo-controlled crossover trial. | 2021 Nov |
1 |
| 29 |
34446852 | Signaling profiles in HEK 293T cells co-expressing GLP-1 and GIP receptors. | 2021 Aug 26 |
2 |
| 30 |
34620002 | Pharmacotherapy for Type 2 Diabetes Mellitus: What's Up and Coming in the Glucagon-Like Peptide-1 (GLP-1) Pipeline? | 2021 Oct 7 |
1 |
| 31 |
34672967 | Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. | 2021 Nov 13 |
1 |
| 32 |
31377992 | Effect of Laparoscopic Sleeve Gastrectomy on Static and Dynamic Measures of Glucose Homeostasis and Incretin Hormone Response 4-Years Post-Operatively. | 2020 Jan |
1 |
| 33 |
31622777 | GIP's effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3-30)NH2. | 2020 Jan |
1 |
| 34 |
31693916 | Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists. | 2020 Mar |
2 |
| 35 |
31706956 | Metabolism of GIP and the contribution of GIP to the glucose-lowering properties of DPP-4 inhibitors. | 2020 Mar |
2 |
| 36 |
31715213 | GIP and the gut-bone axis - Physiological, pathophysiological and potential therapeutic implications. | 2020 Mar |
2 |
| 37 |
31733230 | Blockade of gastric inhibitory polypeptide (GIP) action as a novel means of countering insulin resistance in the treatment of obesity-diabetes. | 2020 Mar |
1 |
| 38 |
31751656 | Effects on pancreatic Beta and other Islet cells of the glucose-dependent insulinotropic polypeptide. | 2020 Mar |
2 |
| 39 |
31756367 | Cellular mechanisms governing glucose-dependent insulinotropic polypeptide secretion. | 2020 Mar |
4 |
| 40 |
31785304 | The role of GIP in α-cells and glucagon secretion. | 2020 Mar |
1 |
| 41 |
31812593 | Cardiovascular biology of the GIP receptor. | 2020 Mar |
2 |
| 42 |
31838219 | Recent advances of GIP and future horizons. | 2020 Mar |
1 |
| 43 |
31848710 | The relationship between plasma GIP and GLP-1 levels in individuals with normal and impaired glucose tolerance. | 2020 May |
2 |
| 44 |
31935429 | Emerging role of GIP and related gut hormones in fertility and PCOS. | 2020 Mar |
2 |
| 45 |
31949084 | No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 Diabetes. | 2020 Mar |
2 |
| 46 |
32068442 | Responses of gut and pancreatic hormones, bile acids, and fibroblast growth factor-21 differ to glucose, protein, and fat ingestion after gastric bypass surgery. | 2020 Apr 1 |
1 |
| 47 |
32077470 | GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals. | 2020 Mar 1 |
3 |
| 48 |
32081451 | The early history of GIP 1969-2000: From enterogastrone to major metabolic hormone. | 2020 Mar |
1 |
| 49 |
32182123 | The effect of acute dual SGLT1/SGLT2 inhibition on incretin release and glucose metabolism after gastric bypass surgery. | 2020 Jun 1 |
3 |
| 50 |
32390941 | Receptor-Mediated Bioassay Reflects Dynamic Change of Glucose-Dependent Insulinotropic Polypeptide by Dipeptidyl Peptidase 4 Inhibitor Treatment in Subjects With Type 2 Diabetes. | 2020 |
1 |